This page covers the management of uterine sarcoma presenting as low-grade uterine adenosarcoma without sarcomatous overgrowth — a distinct histological subtype with a specific evidence-based approach.
Low-grade uterine adenosarcoma without sarcomatous overgrowth is managed similarly to low-grade endometrial stromal sarcoma. Endocrine therapy forms the basis of treatment and is maintained until disease progression or unacceptable adverse effects occur.
The protocol involves endocrine therapy, with the specific agent chosen based on what was used in the prior treatment setting. The complete structured regimen — including agent options and sequencing guidance — is available in the full protocol.
DOI: 10.1136/ijgc-2024-005823
Low-grade adenosarcoma should be managed similarly to patients with LG-ESS, with endocrine therapy until disease progression unless associated with unacceptable adverse effects.
Second-line endocrine therapy with an aromatase inhibitor/progestogen/GnRH analogs/fulvestrant could be considered, with the choice depending on the agent used in the first-line setting. Referral to clinical trials should be considered, if available (IV, C).
View source ↗